Home › a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval
 

Keywords :   


a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval

2016-01-14 10:33:58| Biotech - Topix.net

On December 11, 2015, the United States District Court for the Southern District of Indiana granted a motion to stay a Hatch-Waxman litigation pending the outcome of inter partes reviews on two of the patents-in-suit in the litigation. See Eli Lilly and Company, et al. vs. Accord Healthcare Inc., et al. , No.

Tags: of provide stay basis

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »